A Yeast-Based Screening System for Differential Identification of Poisons and Suppressors of Human Topoisomerase I

Ahmed Seddek¹, Christian Madeira¹, Thirunavukkarasu Annamalai¹, Christopher Mederos¹, Purushottam B. Tiwari², Aaron Z. Welch³, Yuk-Ching Tse-Dinh¹,³,*

¹Department of Chemistry and Biochemistry, Florida International University, Miami, FL 33199, USA
²Department of Oncology, Georgetown University, Washington, DC 20057, USA
³Biomolecular Sciences Institute, Florida International University, Miami, FL 33199, USA

*Correspondence: ytse-dinh@fiu.edu (Yuk-Ching Tse-Dinh)

Academic Editor: Graham Pawelec
Submitted: 19 November 2021 Revised: 23 February 2022 Accepted: 24 February 2022 Published: 9 March 2022

Abstract

Background: Inhibition of human topoisomerase I (TOP1) by camptothecin and topotecan has been shown to reduce excessive transcription of PAMP (Pathogen-Associated Molecular Pattern)-induced genes in prior studies, preventing death from sepsis in animal models of bacterial and SARS-CoV-2 infections. The TOP1 catalytic activity likely resolves the topological constraints on DNA that encodes these genes to facilitate the transcription induction that leads to excess inflammation. The increased accumulation of TOP1-DNA covalent complex (TOP1cc) following DNA cleavage is the basis for the anticancer efficacy of the TOP1 poisons developed for anticancer treatment. The potential cytotoxicity and mutagenicity of TOP1 targeting cancer drugs pose serious concerns for employing them as therapies in sepsis prevention.

Methods: In this study we set up a novel yeast-based screening system that employs yeast strains expressing wild-type or a dominant lethal mutant recombinant human TOP1. The effect of test compounds on growth is monitored with and without overexpression of the recombinant human TOP1.

Results: This yeast-based screening system can identify human TOP1 poisons for anticancer efficacy as well as TOP1 suppressors that can inhibit TOP1 DNA binding or cleavage activity in steps prior to the formation of the TOP1cc.

Conclusions: This yeast-based screening system can distinguish between TOP1 suppressors and TOP1 poisons. The assay can also identify compounds that are likely to be cytotoxic based on their effect on yeast cell growth that is independent of recombinant human TOP1 overexpression.

Keywords: human TOP1; topoisomerase inhibitor; sepsis; inflammation; yeast-based screening system

1. Introduction

Life-threatening complications and fatalities attributable to infections might not be directly caused by the infectious agent. Instead, they might happen as consequences of the host immune responses that are triggered by the infection process. Acute respiratory distress syndrome (ARDS) and pulmonary fibrosis (PF) are two deadly complications of coronavirus infection that are caused by the host immune response to the viral infection [1]. Bacterial infections can also lead to severe immune-related complications, such as ARDS, acute lung injury [2,3], and TB sepsis which has an 80% mortality rate [4]. When microorganisms infect the host, pathogen-associated molecular patterns (PAMPs), which are distinct microbial structures and macromolecules, and damage-associated molecular patterns (DAMPs) that result from damaged host tissues, are identified by pattern recognition receptors (PRRs) that belong to the host immune system. The expression of PRRs through PAMP response genes activates the production of innate immune cells that target and kill the invading pathogens [5,6]. However, excess immune response can cause systemic tissue injuries and sepsis [7]. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response [8] to infection caused by viruses, bacteria or other infectious agents. During sepsis, the overexpression of PAMP response genes leads to the uncontrollable release of inflammatory mediators, such as cytokines and chemokines leading to cytokine storm [9,10].

Topoisomerases play a major role in resolving the topological problems encountered in transcription and replication [11–13]. Human topoisomerase I (TOP1) has been a target for clinically approved cancer treatment [14,15]. FDA-approved drugs that target TOP1 derived from camptothecin are TOP1 poisons that stabilize the enzyme-DNA covalent complex [16,17]. These poisons cause accumulation of topoisomerase I-DNA covalent complex (TOP1cc) and upon collision with replication or transcription proteins forms double-stranded breaks (DSBs) in DNA. Unrepaired DNA DSBs lead to cell death, which is useful in cancer treatment [15,16,18]. An earlier study showed that the activation of PAMP response genes requires human TOP1, and that the depletion and reversible inhibition of TOP1 selectively suppress PAMP response genes [19]. Treatment with camptothecin suppressed PAMP response genes, and rescued mice infected

Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
with Staphylococcus aureus from death by sepsis [19]. Topoisomerase activities can modulate chromatin structure and influence the gene expression patterns relevant for both cancer and inflammation [20]. A recent study also showed that therapy with the FDA-approved TOP1 poison topotecan suppresses lethal inflammation induced by SARS-CoV-2 and protects hamsters against SARS-CoV-2-induced lethal inflammation [21]. However, cytotoxicity associated with topoisomerase poisons is not desirable in sepsis management. Suppressors of human TOP1 that inhibits TOP1 catalytic activity by preventing DNA binding and cleavage by TOP1 may be preferable because they are not expected to cause DNA breaks and cell death. The TOP1 inhibitors that act as such suppressors of TOP1 DNA binding and cleavage can potentially repress PAMP response gene expression and alleviate the excess immune response caused by infections.

Currently, use of radio-labeled DNA substrate is generally needed to conduct the TOP1 DNA cleavage-religation inhibition assays to determine if a TOP1 inhibitor acts as a topoisomerase poison, or if the inhibitor acts as a suppressor to prevent DNA cleavage [22,23]. Yeast-based assays for identification of topoisomerase poisons are easier to perform and do not require handling of radioactive material. The budding yeast Saccharomyces cerevisiae has been used for several decades as a model to study human topoisomerases-targeting drugs [24,25]. S. cerevisiae strains with \( \Delta top1 \) mutation and expressing recombinant human TOP1 were found to be sensitive to camptothecin [25], demonstrating that human TOP1 can be expressed and targeted successfully in yeast by poisons. A human TOP1 mutation, T718A, was reported to mimic the action of camptothecin, leading to the stabilization of the TOP1cc, followed by accumulation of DNA breaks and cell death when the mutant TOP1-T718A enzyme is overexpressed under the control of the GAL1 promoter in yeast with \( \Delta \)top1 mutation [26,27]. We propose that S. cerevisiae with \( \Delta \)top1 mutation that expresses galactose-inducible T718A mutant TOP1 can potentially be used in a screening system for suppressors of human TOP1. These suppressors should reduce the formation of the TOP1cc from the induced TOP1-T718A to rescue the growth of yeast cells overexpressing TOP1-T718A. Fig. 1 illustrates this proposed yeast-based screening system. Recombinant wild-type human TOP1 forms only transient TOP1cc during relaxation reaction. A TOP1 poison like camptothecin will reduce the growth of S. cerevisiae cells when wild-type human TOP1 is overexpressed because of the accumulated DNA breaks. The mutant TOP1-T718A is lethal when overexpressed but cell growth can be rescued to some degree by TOP1 suppressor that prevents the mutant TOP1-T718A from forming the covalent complex. This yeast-based screening system is validated in this study with a newly identified human TOP1 suppressor.

2. Materials and Methods

2.1 Plasmid Clones and Yeast Strains

The S. cerevisiae strain EKY3 (MAT\( \alpha \), ura3–52, his3\( \Delta 200 \), leu2\( \Delta 1 \), trpl\( \Delta 63 \), top1\( \Delta c::TRP1 \)) previously described [28–30] was kindly provided by Dr. Leroy Liu at UMDNJ. The human TOP1 cDNA sequence (Accession No. NM_003286.3) with its starting ATG and termination codon was cloned into plasmid pYES2-TOP1 (Invitrogen). The resulting clone pYES2-TOP1 expresses recombinant human TOP1 under the control of the GAL1 promoter. The T718A substitution was created in pYES2-TOP1 using the Q5 site-directed mutagenesis kit (New England BioLabs) with primers 5'-TCGCCCTGGGAGCCTCAACTCA-3' and 5'-ATCTGTTATTTTCTCCTCGGTCTG-3'.

2.2 Enzyme and Compounds

Recombinant human TOP1 enzyme was purchased from TopoGEN, and also purified from the lysate of S. cerevisiae EKY3/pYES2-TOP1 induced for expression of wild-type human TOP1 with the PrepEase Histidine-Tagged Protein Purification Midi Kit-High Specificity (from Affymetrix) according to the manufacturer's procedures. Camptothecin, myricetin and other flavonoids were purchased from Adooq Bioscience. NSC65860 (3-hydroxy-4-[(4-[(2-hydroxy-3, 6-disulfonaphthalen-1-yl) diazenyl] phenyl) sulfonylphenyl] carbamoyl] phenyl) diazenyl]naphthalene-2, 7-disulfonic acid) was provided by NCI/DTP Open Chemical Repository.

2.3 Human TOP1 Enzyme Inhibition Assay

Human TOP1 was assayed in reaction buffer containing 10 mM Tris-HCl pH 7.9, 1 mM EDTA, 0.15 M NaCl, 0.1% BSA, 0.1 mM spermidine, 5% glycerol [31]. The compounds were added to the enzyme suspended in the buffer, followed by addition of 200 ng of negatively supercoiled DNA in the same buffer for a final volume of 20 \( \mu \)L. The amount of enzyme added was first determined to be the minimal amount required for complete relaxation of the input DNA following 30 min incubation at 37 °C in the presence of 0.5 \( \mu \)L DMSO as control. The reactions were terminated with 4 \( \mu \)L of 6x SDS stop buffer (6% SDS, 6 mg/mL bromophenol blue, 40% glycerol) and was analyzed via electrophoresis in 1% agarose gel with TAE buffer [32]. The gel was stained in a 1 \( \mu \)g/mL solution of ethidium bromide for 30–45 minutes and rinsed for 10–15 minutes in deionized water before photographed over UV light using the ProteinSimple Alphalager Mini system. The percent inhibition was determined with the Alphalager software based on intensity of supercoiled DNA remaining. The average and standard error of results from three experiments was plotted with GraphPad Prism to obtain the IC\(_{50}\) for inhibition.
2.4 Yeast Growth Assay

For spot test of growth inhibition from expression of human TOP1-T718A, EKY3/pYES-TOP1 and EKY3/pYES2-TOP1-T718A were grown from single colonies in 3 mL of Synthetic Complete-Uracil (SC-U) media supplemented with 2% dextrose and incubated overnight at 30 °C. On the second day, the cultures were diluted with SC-U + 2% raffinose 1:50 for a final volume of 3 mL and grown overnight at 30 °C. On the third day, the cultures were diluted into 2 sets with SC-U media + 2% raffinose with OD600 adjusted to 0.1 and 0.5 respectively. Five-fold serial dilutions were then made with SC-U media + 2% raffinose. Five microliters of these serial dilutions were spotted on SC-U agar plates supplemented with either 2% dextrose (expression repressor) or 2% galactose (expression inducer). Agar plates were incubated at 30 °C for 4–5 days.

To monitor growth in 96 well microplates, EKY3/pYES2-TOP1 and EKY3/pYES2-TOP1-T718A cultures were grown from single colonies in SC-U media supplemented with 1% dextrose for 24 hours at 30 °C. The culture was then diluted 1:50 into SC-U supplemented with 1% raffinose, and allowed to grow for a second day at 30 °C. On the day of the experiment, OD600 values of the growing cultures were adjusted to 0.05 with SC-U supplemented with either 1% dextrose or 1% galactose. The compounds tested were diluted serially in the same media in the successive rows of a sterile CELLTREAT polystyrene 96 well round bottom non-treated plate before the addition of an equal volume of the diluted cultures, achieving a final volume of 100 µL of OD600 = 0.025 starting culture in each well. The plate was then incubated at 30 °C for at least 66 hours. OD600 measurements were taken to monitor growth using a Synergy HT plate reader at each time point after 2 min of shaking. Statistical significance of observed differences in OD600 from compound treatment was determined by using the two-way t-test for two independent means.

2.5 Yeast Viable Colony Formation Assay

EKY3/pYES2-TOP1-T718A was grown from single colonies to saturation first in SC-U media supplemented with 1% dextrose for 24 hours at 30 °C. The culture was then diluted 1:50 into SC-U media supplemented with 1% raffinose, and grown for a second day at 30 °C. This saturated culture was used to prepare in 96-well plates 200 µL volume of diluted cultures (final OD600 = 0.025) containing DMSO (1% v/v) or 100 µM NSC65860. Following incubation at 30 °C for the indicated amount of time, 20 µL of cultures were removed for serial dilutions in Phosphate Buffered Saline (PBS) and plated on YPD plates. Viable colonies were counted after incubation at 30 °C for 3 days.
2.6 Preparation of Yeast Lysate for Relaxation Assay and Western Blot Analysis

To confirm recombinant human TOP1 expression under the control of the GAL1 promoter in EKY3 cells, transformants were grown from colonies on plates in Synthetic Complete-Uracil (SC-U) media supplemented with 1% dextrose for 24 hours at 30 °C. The culture was then diluted 1:50 into SC-U supplemented with 1% raffinose, and allowed to grow for a second day at 30 °C. Finally, the OD600 values of the cultures were adjusted to 0.05 with SC-U media supplemented with either 1% dextrose (expression repressor) or 1% galactose (expression inducer) and allowed to grow for 66 hours at 30 °C. Cell pellets were collected by centrifugation at 16,000 × g for 5 min.

For relaxation activity assay, cells were resuspended in a cell breaking buffer consisting of 0.15 M NaCl, 0.1% BSA, 0.1 mM spermidine, and 5% glycerol that composed of 10 mM Tris HCl, pH 7.9, 1 mM EDTA, and DNA coordinates only and I-TASSER [35] was used to model missing residues to generate the full length structure of human TOP1. A 10 ns molecular dynamics (MD) simulation was conducted for this newly generated full length human TOP1-DNA structure using the NAMD simulation package [38]. The topology and parameter files used to generate and simulate the structure are as described previously [34]. Protein only coordinates (full length human TOP1) from the covalent complex after 10 ns MD simulation was then selected as the target structure for docking. AutoDock Tools [39] was used to generate a pdbqt file of the human TOP1 structure. Finally, AutoDock vina [40] was used to dock the NSC65860 against human TOP1 target structure. The dimensions of the search box was 90 × 120 × 130 Å³ that covered the entire human TOP1. Five independent dockings were performed against the same human TOP1 target using the same NSC65860 pdbqt file as mentioned above. The docked conformation with the highest affinity among the affinities of the top predicted model from the results of each docked result was then selected as the best conformation. VMD [41] was used to generate the docked position of the best docked NSC65860 structure against human TOP1 and to analyze hydrogen bonds. An atomic distance of 3.5 Å and angle cut off of 30 degrees were used to predict hydrogen bonding.

2.7 Docking of NSC65860 to Human TOP1

We performed docking of NSC65860 against a human TOP1 structure following previously published procedures [34]. Briefly, the 2D structure of NSC65860 (obtained from PubChem) was converted to a 3D structure. A random 3D ligand conformer was then obtained and converted to a pdbqt file by adding polar hydrogens using Open Babel [35]. PDB 1K4T [36] was used to extract human TOP1 and DNA coordinates only and I-TASSER [37] was used to model missing residues to generate the full length structure of human TOP1. A 10 ns molecular dynamics (MD) simulation was conducted for this newly generated full length human TOP1-DNA structure using the NAMD simulation package [38]. The topology and parameter files used to generate and simulate the structure are as described previously [34]. Protein only coordinates (full length human TOP1) from the covalent complex after 10 ns MD simulation was then selected as the target structure for docking. AutoDock Tools [39] was used to generate a pdbqt file of the human TOP1 structure. Finally, AutoDock vina [40] was used to dock the NSC65860 against human TOP1 target structure. The dimensions of the search box was 90 × 120 × 130 Å³ that covered the entire human TOP1. Five independent dockings were performed against the same human TOP1 target using the same NSC65860 pdbqt file as mentioned above. The docked conformation with the highest affinity among the affinities of the top predicted model from the results of each docked result was then selected as the best conformation. VMD [41] was used to generate the docked position of the best docked NSC65860 structure against human TOP1 and to analyze hydrogen bonds. An atomic distance of 3.5 Å and angle cut off of 30 degrees were used to predict hydrogen bonding.

3. Results

3.1 Inducible Expression of Human TOP1 in EKY3 Yeast Cells

To validate the catalytic function of recombinant human TOP1 induced in EKY3 yeast cells, EKY3 cell lysates were prepared and assayed with supercoiled plasmid DNA as substrate. The relaxation activity of the human TOP1 in the lysates were compared with purified recombinant human TOP1 (from TopoGEN) as control. As shown in Fig. 2, EKY3/pYES2-TOP1 cells expressed active human TOP1 in the presence of galactose as inducer of the GAL1 promoter (lane 3). The human TOP1 activity was present at lower level when the GAL1 promoter was repressed by
dextrose (lane 5). Under our assay conditions, we could not detect any relaxation activity in the soluble lysates of EKY3/pYES2-TOP1-T718A cells growth in presence of either dextrose or galactose (Fig. 2, lanes 4 and 6).

3.2 Growth Inhibition of EKY3 Yeast Cells from Induction of Mutant TOP1-T718A

We confirmed that the accumulation of the covalent intermediate formed by recombinant TOP1-T718A in EKY3 led to galactose-dependent growth inhibition. Growth observed from serial dilutions spotted on agar plates (Fig. 3A) showed equal growth of wild-type and mutant transformants on agar plate with 2% dextrose but no growth for transformant of mutant TOP1-T718A on agar plate with 2% galactose. We tested lower galactose concentrations for induction of TOP1-T718A expression in 96 well microplates so that the rescue of growth by TOP1 suppressors could be more readily observed in screening assays. Growth inhibition of EKY3 from induction of mutant TOP1-T718A could be readily detected in 96 well microplates when the OD600 readings of cultures in 1% galactose or dextrose were monitored (Fig. 3B). Galactose induction of wild-type TOP1 is well tolerated in both assays.

3.3 Effect of Camptothecin on the Growth of EKY3/pYES2-TOP1 and EKY3/pYES2-TOP1-T718A

Camptothecin is an extensively characterized human TOP1 poison with synthetic analogs that are used clinically in anticancer treatment [14,17]. Addition of camptothecin to culture of EKY3/pYES2-TOP1 resulted in growth inhibition to a much greater extent in the presence of galactose versus dextrose, as expected from the toxic effect from the trapping of the covalent complex formed by induced recombinant TOP1 (Fig. 4). In contrast, camptothecin had relatively little effect on growth of EKY3/pYES2-TOP1-

Fig. 2. Activity of recombinant human TOP1 expressed in EKY3. Lane 1. Supercoiled plasmid DNA substrate. Lane 2. 1 U of human TOP1 from TopoGEN added. Lane 3–6. Equal amounts of lysates of EKY3 transformed with wild-type pYES2-TOP1 plasmid (lanes 3, 5) or mutant pYES2-TOP1-T718A plasmid (lanes 4, 6) were compared. Expression of recombinant human TOP1 was induced by galactose (lanes 3, 4) or repressed by dextrose (lanes 5, 6). S, supercoiled DNA; N, nicked DNA; FR, fully relaxed DNA; PR, partially relaxed DNA. The lanes shown here are from the same gel.

Fig. 3. Galactose-dependent growth inhibition of EKY3 from expression of TOP1-T718A mutant. (A) EKY3/pYES2-TOP1 and EKY3/pYES2-TOP1-T718A saturated cultures in SC-U media with 2% raffinose were diluted to OD600 = 0.1 (top 2 rows) or 0.5 (bottom two rows) before 5-fold serial dilutions were spotted on SC-U agar plates supplemented with either 2% dextrose or galactose. (B) Growth curves of EKY3/pYES2-TOP1 and EKY3/pYES2-TOP1-T718A in SC-U media supplemented with 1% dextrose or galactose.
T718A with expression of the mutant TOP1-T718A induced by galactose, since this mutant protein already forms a stabilized TOP1cc. These results demonstrate that utility of the yeast screening system for studying the TOP1 poisons. The slight increase in OD values observed for camptothecin treatment of EKY3/pYES2-TOP1-T718A is not statistically significant, but could be due to other unknown effects of camptothecin.

3.4 Characterization of Natural Product TOP1 Inhibitor with Yeast-Based Assay

In addition to camptothecin, natural products have been reported in the literature as human TOP1 inhibitors [42–45]. It is not always clear if these natural products act as poisons or suppressors in their TOP1 inhibition mechanism [45]. A set of nine flavonoids and similar compounds (Supplementary Fig. 1) were first tested for inhibition of TOP1 relaxation activity at up to 250 μM concentration. Myricetin was the only compound found in this preliminary study to inhibit the relaxation activity of recombinant human TOP1 expressed in yeast completely. Follow-up assay of serial dilution of myricetin showed that the IC$_{50}$ for inhibition of more highly purified human TOP1 from TopoGEN is ~10 μM (Fig. 5A). Testing of myricetin in the yeast-based assay (Fig. 5B) showed that it inhibited growth of EKY3/pYES2-TOP1 with either galactose or dextrose in the media, with a greater degree of growth inhibition in galactose containing medium. There is also no increase in the growth of EKY3/pYES2-TOP1-T718A. These results suggested that in addition to inhibiting TOP1 activity as a poison, myricetin can inhibit yeast cell growth with TOP1-independent mechanism. Myricetin was found previously to inhibit both human TOP1 and TOP2α [42,44]. The yeast-based screening assay described here is thus useful for identifying TOP1 inhibitors that may have other cellular targets.

3.5 Characterization of a New TOP1 Suppressor Candidate

Compounds with functional groups that may compete for nucleic acid binding to topoisomerases were obtained from NCI Developmental Therapeutics and tested for preventing human TOP1 from relaxing supercoiled plasmid DNA in gel-based assay as well as the yeast-based screening assay described here. NSC65860 was found to prevent the relaxation of supercoiled plasmid DNA by human TOP1, with IC$_{50}$ of 0.89 μM (Fig. 6A). When incubated with supercoiled plasmid DNA in the absence of human TOP1, NSC65860 had no effect on the DNA electrophoretic mobility (Supplementary Fig. 2). When NSC65860 was added to relaxed DNA and incubated further with human TOP1, there was no significant change in plasmid supercoiling as seen with ethidium bromide as a positive control for DNA intercalator in the same experiment (Supplementary Fig. 3), ruling out the possibility that the effect of NSC65860 on plasmid DNA relaxation by human TOP1 shown in Fig. 6A was due to DNA intercalation.

NSC65860 had no significant effect on the growth of EKY3/pYES2-TOP1 in the presence of either dextrose or galactose (Fig. 6B). In the presence of dextrose to repress the expression of the toxic mutant TOP1-T718A protein, NSC65860 had also little effect on growth of EKY3/pYES2-TOP1-T718A. However the growth of EKY3/pYES2-TOP1-T718A in the presence of galactose was enhanced significantly by the addition of NSC65860, with up to 3.5-fold increase in OD600 at 66 hours (Fig. 6B). This is consistent with NSC65860 acting as TOP1 suppressor to prevent the formation of intracellular TOP1-T718A covalent complex from the induced toxic mutant TOP1. The protective effect of NSC65860 on EKY3/pYES2-TOP1-T718A has been confirmed with measurement of CFU/mL following culture in SC-U media with 1% galactose (Supplementary Table 1 and Supplementary Fig. 4). NSC65860 does not affect growth of EKY3/pYES2-TOP1 in media with dextrose (Supplementary Fig. 5), so it is unlikely to have significant effect on any possible targets in yeast that may result in growth inhibition. It needs to be confirmed that treatment of EKY3 with NSC65860 did not impair the induction of recombinant protein expression from the GAL1 promoter. Western blot with antibodies against human TOP1 was used to show that treatment with as much as 100 μM NSC65850 had little or no effect on the production of recombinant human TOP1 from the GAL1 promoter following induction with 1% galactose (Fig. 7). The induction of TOP1-T718A has also been examined by western blot to confirm that NSC65860 did not affect the induction of the mutant TOP1 by galactose (Supplementary Fig. 6).

3.6 Docking of NSC65860 Near Human TOP1 Active Site

Molecular docking is a widely used computational technique to predict ligand-receptor complexes. In this work, we used AutoDock vina to predict a possible binding site for NSC65860 when human TOP1 was used as a target. The structure of NSC65860 is shown in Fig. 8A. Notably, the search box used in our docking procedure covered the entire TOP1 structure allowing NSC65860 to dock randomly in the target. The human TOP1 target structure is taken from its covalent complex with DNA. Fig. 8B shows the best-predicted docked position of NSC65860 in human TOP1. Our result predicts that the region near the active site tyrosine (TYR732) is a possible binding site for NSC65860. Analysis of the docked NSC65860 predicted that the three amino acid residues ARG364, ARG488, and TYR501 establish hydrogen bindings with NSC65860. The hydrogen bonds are shown as dashed lines in magenta color in Fig. 8B.
Fig. 4. Effect of camptothecin on growth of EKY3/pYES2-TOP1 and EKY3/pYES-TOP1-T718A in media with dextrose or galactose. (A) Representative growth curves with increasing concentrations of camptothecin present. (B) Effect of camptothecin on relative OD600 of cultures after 66 hours in dextrose media with non-induced versus galactose media with induced expression of wild-type (WT) or T178A mutant recombinant human TOP1. ****: \( p < 0.0001 \), **: \( p < 0.01 \), ns, not significant.

4. Discussion

The lethal mutant human TOP1-T718A enzyme forms a stabilized covalent complex following DNA cleavage, leading to accumulation of DNA breaks and eventually cellular death when overexpressed from the GAL1 promoter in yeast cells cultured in media containing galactose [27]. *S. cerevisiae* cells overexpressing TOP1-T718A can be used as a model to screen for suppressors of human TOP1 that inhibit DNA binding and cleavage by TOP1. Such suppressors can be expected to reduce the lethal effect of TOP1-T718A expression. This would increase the viability of these cells when grown in media with galactose inducer. The TOP1 catalytic activity is not required for yeast cell growth. As discussed previously [46], cytotoxicity from action on other cellular targets is an important concern for identifying specific human TOP1 suppressors or poisons that can be addressed through yeast-based assay. A specific
human TOP1 suppressor should not negatively impact the growth rates of yeast cells expressing WT human TOP1. In this study, we used yeast EKY3 transformed with WT or T718A mutant TOP1 clones to demonstrate that compound NSC65860 is likely to be a human TOP1 suppressor based on results from this yeast-based assay. The growth of EKY3/pYES-TOP1-T718A in the presence of galactose was enhanced by >3.5-fold while growth in the presence of dextrose was not changed significantly. NSC65860 also did not affect growth of EKY3/pYES-TOP1 in either galactose or dextrose containing media. Western blot analysis of soluble lysates of NSC65860-treated EKY3 cells showed that it does not affect the expression of recombinant human TOP1 from the GAL1 promoter, in support of its action as a suppressor that inhibits DNA binding or cleavage by human TOP1. We currently do not know what steps in the TOP1 reaction may be inhibited by NSC65860. Additional research is required to determine the exact mechanism of action of NSC65860 and its impacts on PAMP gene expression in human cells, so that it can potentially be optimized into a candidate for sepsis treatment.

The results reported here provide validation that this yeast-based screening system could be used as a rapid and economical screening approach for identifying specific human TOP1 suppressors. Compared to enzyme-based gel electrophoresis assay, the yeast-based assay would require less resources to scale up for screening of a large library of molecules for TOP1 inhibitors. Candidates for either TOP1 suppressors or poisons can be identified based on the differential effects of the compound on growth of EKY3/pYES-TOP1 and EKY3/pYES-TOP1-718A in media containing dextrose versus galactose. A specific human TOP1 poison would diminish growth only when WT TOP1 expression is induced by galactose. Myricetin resulted in most significant growth suppression of EKY3 with galactose induction of WT TOP1 to indicate that it can act as a TOP1 poison, as reported in previous research [42,44]. There was also some degree of suppression of growth of EKY3/pYES-TOP1 in
Fig. 6. Testing of NSC65860 in human TOP1 relaxation and yeast-based growth assay. (A) Human TOP1 (0.3 U from TopoGEN) was assayed for relaxation of supercoiled plasmid DNA in the presence of serial dilutions of NSC65860. Lane 1: no enzyme; lane 2: DMSO control; lane 3: 25 µM CPT; lanes 4–9: 5, 2.5, 1.2, 0.62, 0.31, 0.16 µM NSC65860. S, supercoiled DNA; N, nicked DNA; FR, fully relaxed DNA; PR, partially relaxed DNA. Results from three replicates were plotted to obtain the IC50. (B) Effect of NSC65860 on relative OD600 of cultures after 66 hours in 1% dextrose media with non-induced or 1% galactose media with induced expression of wild-type (WT) or T178A mutant recombinant human TOP1. *: p < 0.05; **: p < 0.01; ***: p < 0.001.

Fig. 7. Western blot analysis of effect of NSC65860 on induction of GAL1 promoter. Total lysates of equal number of EKY3/pYES2-TOP1 cells grown in media with 1% galactose or dextrose, with and without treatment of 100 µM NSC65860 were analyzed in duplicates by SDS-PAGE followed by western blots with antibodies against human TOP1 and actin.
the presence of dextrose, suggesting that myricetin can affect yeast cell viability in mode of action that does not involve TOP1 inhibition. Myricetin is likely to act on an essential target in yeast, with TOP2 being just one of the possibilities. Significant growth suppression of EKY3/pYES-TOP1 in dextrose containing media can thus be an indication that the molecule is not likely to be a selective human TOP1 inhibitor and may not be a good candidate for consideration in further investigation of TOP1 poisons or suppressors for potential clinical applications in cancer or infectious disease treatment. This useful information on selectivity at the cellular level can be obtained readily from this yeast-based screening system to facilitate planning of development of human TOP1 suppressors into drug leads for reducing harmful inflammatory response during bacterial and viral infections.

5. Conclusions

The yeast-based screening system described in this study can be used to identify human TOP1 inhibitors acting as poisons that trap TOP1cc, or as suppressors that prevent DNA cleavage by TOP1. The yeast growth inhibition assays can complement the relaxation inhibition assay to provide information on the mode of action and selectivity of human TOP1 inhibitors. Compounds that are likely to be cytotoxic can also be identified based on their effect on yeast cell growth that is independent of recombinant human TOP1 overexpression.

Abbreviations

PAMP, pathogen-associated molecular pattern; ARDS, acute respiratory distress syndrome; PRR, pattern
recognition receptor; TOP1, Topoisomerase I; TOP1cc, TOP1 covalent complex; CPT, camptothecin; WT, wild-type.

**Author contributions**

YCDT, TA and AW conceived and designed the experiments; AS, CM (Christian Madeira), TA, PT performed the experiments; AS, CM (Christian Madeira), TA, PT and YCDT analyzed the data; CM (Christopher Medros) and AW contributed reagents. AS and YCDT prepared the manuscript. All authors have read and approved the manuscript.

**Ethics approval and consent to participate**

Not applicable.

**Acknowledgment**

We thank Norhan Mohammed for technical assistance. We acknowledge the NCI/DTPOpen Chemical Repository (http://dtp.cancer.gov) for supply of NSC65860.

**Funding**

This research was supported by the Florida International University Food Science Initiative with funding from the College of Arts, Sciences, Education and the Chaplin School of Hospitality and Tourism Management. Ahmed Seddekwassupported by a FIU University Graduate School of Hospitality and Tourism Management. Ahmed Seddekwassupported by a FIU University Graduate School of Hospitality and Tourism Management. Ahmed Seddekwassupported by a FIU University Graduate School of Hospitality and Tourism Management.

**Conflict of interest**

The authors declare no conflict of interest.

**Supplementary material**

Supplementary material associated with this article can be found, in the online version, at https://www.impress.com/journal/FBL/27/3/10.31083/j.fbl2703093.

**References**

[1] Liang Y, Wang ML, Chien CS, Yarmishyn AA, Yang YP, Lai WY, et al. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection. Frontiers in Immunology. 2020; 11: 1022.

[2] Kumar V. Pulmonary Innate Immune Response Determines the Outcome of Inflammation During Pneumonia and Sepsis-Associated Acute Lung Injury. Frontiers in Immunology. 2020; 11: 1722.

[3] Deshpande R, Zou C. Pseudomonas Aeruginosa Induced Cell Death in Acute Lung Injury and Acute Respiratory Distress Syndrome. International Journal of Molecular Sciences. 2020; 21: 5356.

[4] Shah M, Reed C. Complications of tuberculosis. Current Opinion in Infectious Diseases. 2014; 27: 403–410.

[5] Janeway CA, Medzhitov R. Innate Immune Recognition. Annual Review of Immunology. 2002; 20: 197–216.

[6] Beutler B, Eideneschken C, Crotz K, Imler J, Takeuchi O, Hoffmann JA, et al. Genetic analysis of resistance to viral infection. Nature Reviews Immunology. 2007; 7: 753–766.

[7] Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine and Growth Factor Reviews. 2002; 13: 413–421.

[8] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Anne D, Bauer M, et al. The third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Journal of the American Medical Association. 2016; 315: 801–810.

[9] Bosmann M, Ward PA. The inflammatory response in sepsis. Trends in Immunology. 2013; 34: 129–136.

[10] Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets—an updated view. Mediators of Inflammation. 2013; 2013: 165974.

[11] McKie SJ, Neuman KC, Maxwell A. DNA topoisomerases: Advances in understanding of cellular roles and multi-protein complexes via structure-function analysis. BioEssays. 2021; 43: 2000286.

[12] Pommier Y, Sun Y, Huang SN, Nitiss JL. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nature Reviews Molecular Cell Biology. 2016; 17: 703–721.

[13] Soren BC, Dasari JB, Ottaviani A, Iacovelli F, Fiorani P. Topoisomerase IB: a relaxing enzyme for stressed DNA. Cancer Drug Resistance. 2020; 3: 18-25.

[14] Thomas A, Pommier Y. Targeting Topoisomerase I in the Era of Precision Medicine. Clinical Cancer Research. 2019; 25: 6581–6589.

[15] Bjornsti M, Kaufmann SH. Topoisomerases and cancer chemotherapy: recent advances and unanswered questions. F1000Research. 2019; 8: F1000 Faculty Rev-1704.

[16] Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chemical Biology. 2013; 8: 82–95.

[17] Cinelli MA. Topoisomerase 1B poisons: over a half-century of drug leads, clinical candidates, and serendipitous discoveries. Medicinal Research Reviews. 2019; 39: 1294–1337.

[18] Delgado JL, Hsieh C, Chan N, Hiasa H. Topoisomerases as anticancer targets. Biochemical Journal. 2018; 475: 373–398.

[19] Rialdi A, Campisi L, Zhao N, Lagda AC, Pietzsch C, Ho JSY, et al. Topoisomerase I inhibition suppresses inflammatory genes and protects from death by inflammation. Science. 2016; 352: aad7993.

[20] Marazzi I, Greenbaum BD, Low DHP, Guccione E. Chromatin dependencies in cancer and inflammation. Nature Reviews Molecular Cell Biology. 2018; 19: 245–261.

[21] Ho JSY, Mok BW, Campisi L, Jordan T, Yildiz S, Parameswaran S, et al. Top1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell. 2021; 184: 2618–2632.e17.

[22] Fiorani P, Henn CL, Benedetti P, Bjornsti MA. Drug-induced stabilization of covalent DNA topoisomerase I-DNA intermediates. DNA cleavage assays. Methods in Molecular Biology. 2001; 95: 291–301.

[23] Dexeheimer TS, Pommier Y. DNA cleavage assay for the identification of topoisomerase I inhibitors. Nature Protocols. 2008; 3: 1736–1750.

[24] Nitiss J, Wang JC. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proceedings of the National Academy of Sciences. 1988; 85: 7501–7505.

[25] Bjornsti MA, Benedetti P, Viglianti GA, Wang JC. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Research. 1989; 49: 6318–6323.

[26] Fiorani P, Amatuda JF, Silvestri A, Butler RH, Bjornsti MA, Benedetti P. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity. Molecular Pharmacology. 1999; 56: 1105–1115.
Losasso C, Cretaio E, Palle K, Pattarello L, Bjornsti M, Benedetti P. Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality. The Journal of Biological Chemistry. 2007; 282: 9855–9864.

Kauh EA, Bjornsti MA. SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I. Proceedings of the National Academy of Sciences of the United States of America. 1995; 92: 6299–6303.

Megenigal MD, Fertala J, Bjornsti MA. Alterations in the catalytic activity of yeast DNA topoisomerase I result in cell cycle arrest and cell death. The Journal of Biological Chemistry. 1997; 272: 12801–12808.

Daroui P, Desai SD, Li T, Liu AA, Liu LF. Hydrogen peroxide induces topoisomerase I-mediated DNA damage and cell death. The Journal of Biological Chemistry. 2004; 279: 14587–14594.

Sandhaus S, Chapagain PP, Tse-Dinh Y. Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays. Scientific Reports. 2018; 8: 1437.

Narula G, Tse-Dinh Y. Residues of E. coli topoisomerase I conserved for interaction with a specific cytosine base to facilitate DNA cleavage. Nucleic Acids Research. 2012; 40: 9233–9243.

Kushnirov VV. Rapid and reliable protein extraction from yeast. Yeast. 2000; 16: 857–860.

Tiwari PB, Chapagain PP, Seddek A, Annamalai T, Uren A, Tse-Dinh Y. Covalent Complex of DNA and Bacterial Topoisomerase: Implications in Antibacterial Drug Development. ChemMedChem. 2020; 15: 623–631.

O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: an open chemical toolbox. Journal of Cheminformatics. 2011; 3: 33.

Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99: 15387–15392.

Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nature Protocols. 2010; 5: 725–738.

Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable molecular dynamics with NAMD. Journal of Computational Chemistry. 2005; 26: 1781–1802.

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry. 2009; 30: 2785–2791.

Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multi threading. Journal of Computational Chemistry. 2010; 31: 455–461.

Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. Journal of Molecular Graphics. 1996; 14: 33–38, 27–28.

Constantinou A, Melta R, Runyan C, Rao K, Vaughan A, Moon R. Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. Journal of Natural Products. 1995; 58: 217–225.

Webb MR, Ebeler SE. Comparative analysis of topoisomerase IB inhibition and DNA intercalation by flavonoids and similar compounds: structural determinates of activity. The Biochemical Journal. 2004; 384: 527–541.

López-Lázaro M, Willmore E, Austin CA. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells. Mutation Research. 2010; 696: 41–47.

Ottaviani A, Iacovelli F, Fiorani P, Desideri A. Natural Compounds as Therapeutic Agents: The Case of Human Topoisomerase IB. International Journal of Molecular Sciences. 2021; 22: 4138.

Pommier Y. Diversity of DNA topoisomerase I and inhibitors. Biochimie. 1998; 80: 255–270.